ABSTRACT
A novel series of tetrafluoro and hexafluoro acyclic nucleosides and their phosphoramidates were successfully prepared from commercially available 2,2,3,3-tetrafluoro-1,4-butanediol and 2,2,3,3,4,4-hexafluoro-1,5-pentanediol in four to six steps. Their ability to block HIV, HCV, HSV-1, and HBV replication along with their cytotoxicity toward HepG2, human lymphocyte, CEM, and Vero cells was assessed.
Acknowledgments
We wish to thank Mervi Detorio and Cathy Montero for excellent technical assistance.
Funding
This work was supported in part by NIH grant 5P30-AI-50409 (CFAR). We would like to acknowledge the Egyptian Ministry of Higher Education and the Egyptian Educational Culture Bureau in USA for funding Dr. Sawsan's Ph.D. studies at Emory University. Dr. Schinazi is the Chairman and a major shareholder of CocrystalPharma, Inc. Emory received no funding from CocrystalPharma, Inc. to perform this work and vice versa.